Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
413 | 3505 | 34.5 | 75% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
171 | 3 | MONASCUS//CITRININ//MONASCUS PURPUREUS | 58457 |
419 | 2 | STATINS//EZETIMIBE//SIMVASTATIN | 16502 |
413 | 1 | STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN | 3505 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | STATINS | authKW | 318274 | 15% | 7% | 518 |
2 | LOW DENSITY LIPOPROTEIN CHOLESTEROL | authKW | 131976 | 3% | 14% | 109 |
3 | ATORVASTATIN | authKW | 112556 | 4% | 8% | 153 |
4 | LIPID LOWERING | authKW | 107821 | 1% | 26% | 48 |
5 | ROSUVASTATIN | authKW | 101007 | 3% | 13% | 89 |
6 | HYPERCHOLESTEROLEMIA | authKW | 92517 | 6% | 5% | 198 |
7 | LIPID LOWERING DRUGS | authKW | 85598 | 1% | 23% | 43 |
8 | CORONARY HEART DISEASE | authKW | 85001 | 7% | 4% | 257 |
9 | LIPID LOWERING THERAPY | authKW | 82193 | 1% | 23% | 41 |
10 | LDL C | authKW | 68646 | 1% | 16% | 48 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Cardiac & Cardiovascular System | 32096 | 38% | 0% | 1325 |
2 | Medicine, General & Internal | 15574 | 31% | 0% | 1095 |
3 | Peripheral Vascular Diseases | 3865 | 10% | 0% | 363 |
4 | Health Care Sciences & Services | 2227 | 6% | 0% | 203 |
5 | Pharmacology & Pharmacy | 1762 | 15% | 0% | 536 |
6 | Health Policy & Services | 1453 | 4% | 0% | 126 |
7 | Primary Health Care | 1059 | 2% | 0% | 64 |
8 | Endocrinology & Metabolism | 428 | 6% | 0% | 193 |
9 | Geriatrics & Gerontology | 398 | 2% | 0% | 73 |
10 | Medicine, Research & Experimental | 148 | 4% | 0% | 128 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANAL COST EFFECT CARE | 64525 | 0% | 44% | 17 |
2 | SECT ATHEROSCLEROSIS LIPID | 36290 | 0% | 83% | 5 |
3 | CHOLESTEROL EDUC PROGRAM | 34840 | 0% | 100% | 4 |
4 | US MED SCI AFFAIRS | 28445 | 0% | 47% | 7 |
5 | INDEPENDENT LIPIDOL | 26130 | 0% | 100% | 3 |
6 | HEART DIS PREVENT CLIN | 25328 | 0% | 36% | 8 |
7 | CARDIAC REHABIL CHOLESTEROL CLIN | 19596 | 0% | 75% | 3 |
8 | POST CABG COORDINATING | 19596 | 0% | 75% | 3 |
9 | DIENST ENDOCRINOL METAB VOEDING | 17420 | 0% | 100% | 2 |
10 | EFFECTIVENESS EVALUAT UNIT | 17420 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | AMERICAN JOURNAL OF CARDIOLOGY | 31488 | 9% | 1% | 311 |
2 | ATHEROSCLEROSIS SUPPLEMENTS | 18068 | 1% | 9% | 24 |
3 | JOURNAL OF CARDIOVASCULAR RISK | 15966 | 1% | 9% | 21 |
4 | AMERICAN JOURNAL OF MANAGED CARE | 15584 | 2% | 3% | 70 |
5 | EUROPEAN HEART JOURNAL SUPPLEMENTS | 14895 | 1% | 4% | 42 |
6 | CARDIOVASCULAR THERAPY AND PREVENTION | 12669 | 1% | 4% | 33 |
7 | CURRENT OPINION IN LIPIDOLOGY | 12081 | 1% | 3% | 43 |
8 | CURRENT MEDICAL RESEARCH AND OPINION | 10890 | 2% | 2% | 75 |
9 | CLINICAL THERAPEUTICS | 8024 | 2% | 1% | 68 |
10 | INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 7975 | 2% | 1% | 62 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | STATINS | 318274 | 15% | 7% | 518 | Search STATINS | Search STATINS |
2 | LOW DENSITY LIPOPROTEIN CHOLESTEROL | 131976 | 3% | 14% | 109 | Search LOW+DENSITY+LIPOPROTEIN+CHOLESTEROL | Search LOW+DENSITY+LIPOPROTEIN+CHOLESTEROL |
3 | ATORVASTATIN | 112556 | 4% | 8% | 153 | Search ATORVASTATIN | Search ATORVASTATIN |
4 | LIPID LOWERING | 107821 | 1% | 26% | 48 | Search LIPID+LOWERING | Search LIPID+LOWERING |
5 | ROSUVASTATIN | 101007 | 3% | 13% | 89 | Search ROSUVASTATIN | Search ROSUVASTATIN |
6 | HYPERCHOLESTEROLEMIA | 92517 | 6% | 5% | 198 | Search HYPERCHOLESTEROLEMIA | Search HYPERCHOLESTEROLEMIA |
7 | LIPID LOWERING DRUGS | 85598 | 1% | 23% | 43 | Search LIPID+LOWERING+DRUGS | Search LIPID+LOWERING+DRUGS |
8 | CORONARY HEART DISEASE | 85001 | 7% | 4% | 257 | Search CORONARY+HEART+DISEASE | Search CORONARY+HEART+DISEASE |
9 | LIPID LOWERING THERAPY | 82193 | 1% | 23% | 41 | Search LIPID+LOWERING+THERAPY | Search LIPID+LOWERING+THERAPY |
10 | LDL C | 68646 | 1% | 16% | 48 | Search LDL+C | Search LDL+C |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | BAIGENT, C , KEECH, A , KEARNEY, PM , BLACKWELL, L , BUCK, G , POLLICINO, C , KIRBY, A , SOURJINA, T , PETO, R , COLLINS, R , ET AL (2005) EFFICACY AND SAFETY OF CHOLESTEROL-LOWERING TREATMENT: PROSPECTIVE META-ANALYSIS OF DATA FROM 90,056 PARTICIPANTS IN 14 RANDOMISED TRIALS OF STATINS.LANCET. VOL. 366. ISSUE 9493. P. 1267-1278 | 27 | 71% | 3243 |
2 | WENG, TC , YANG, YHK , LIN, SJ , TAI, SH , (2010) A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE THERAPEUTIC EQUIVALENCE OF STATINS.JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. VOL. 35. ISSUE 2. P. 139 -151 | 57 | 78% | 113 |
3 | GRUNDY, SM , CLEEMAN, JI , MERZ, CNB , BREWER, HB , CLARK, LT , HUNNINGHAKE, DB , PASTERNAK, RC , SMITH, SC , STONE, NJ , (2004) IMPLICATIONS OF RECENT CLINICAL TRIALS FOR THE NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES.CIRCULATION. VOL. 110. ISSUE 2. P. 227-239 | 27 | 66% | 3252 |
4 | WARD, S , JONES, ML , PANDOR, A , HOLMES, M , ARA, R , RYAN, A , YEO, W , PAYNE, N , (2007) A SYSTEMATIC REVIEW AND ECONOMIC EVALUATION OF STATINS FOR THE PREVENTION OF CORONARY EVENTS.HEALTH TECHNOLOGY ASSESSMENT. VOL. 11. ISSUE 14. P. 1 -+ | 112 | 41% | 89 |
5 | ADAMS, SP , TSANG, M , WRIGHT, JM , (2012) LIPID LOWERING EFFICACY OF ATORVASTATIN.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 12. P. - | 193 | 22% | 1 |
6 | GUMBS, PD , VERSCHUREN, MWM , MANTEL-TEEUWISSE, AK , DE WIT, AG , DE BOER, A , KLUNGEL, OH , (2007) ECONOMIC EVALUATIONS OF CHOLESTEROL-LOWERING DRUGS - A CRITICAL AND SYSTEMATIC REVIEW.PHARMACOECONOMICS. VOL. 25. ISSUE 3. P. 187-199 | 59 | 74% | 4 |
7 | CHEN, CY , CHUANG, SY , FANG, CC , HUANG, LC , HSIEH, IC , PAN, WH , YEH, HI , WU, CC , YIN, WH , CHEN, JW , (2014) GENDER DISPARITIES IN OPTIMAL LIPID CONTROL AMONG PATIENTS WITH CORONARY ARTERY DISEASE.JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS. VOL. 21. ISSUE . P. S20 -S28 | 45 | 75% | 4 |
8 | MCTAGGART, F , JONES, P , (2008) EFFECTS OF STATINS ON HIGH-DENSITY LIPOPROTEINS: A POTENTIAL CONTRIBUTION TO CARDIOVASCULAR BENEFIT.CARDIOVASCULAR DRUGS AND THERAPY. VOL. 22. ISSUE 4. P. 321 -338 | 74 | 49% | 46 |
9 | TAYLOR, F , HUFFMAN, MD , MACEDO, AF , MOORE, THM , BURKE, M , SMITH, GD , WARD, K , EBRAHIM, S , (2013) STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 1. P. - | 69 | 36% | 72 |
10 | DURRINGTON, P , (2002) THE HUMAN AND ECONOMIC COSTS OF UNDERTREATMENT WITH STATINS.INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. VOL. 56. ISSUE 5. P. 357 -368 | 54 | 82% | 15 |
Classes with closest relation at Level 1 |